Samrat Pharmachem Ltd (SAMRATPH)

Loading page…

Samrat Pharmachem Ltd (SAMRATPH) · mywealthgrid

About

Samrat Pharmachem Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹72 Cr

P/E

10.1×

P/B

1.1×

Dividend yield

0.9%

ROE

-4.7%

ROCE

-3%

Debt / equity

0.16

OPM

-0.7%

EPS (TTM)

₹23.0

Book value

₹220.6

52-week high

—

52-week low

—

2,224 historical price candles were omitted because the exchange source has not been verified.

₹232.9-1.3%1Y

Quick read

rule-based

Pros

+High return on capital employed of 34.3%

Cons

−Low return on equity of 3% (3-yr avg)
−Weak interest coverage of -2.1×
−Low dividend payout of 8.7% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

38/100

Business quality: 18
Growth: 0
Valuation: 96

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	62	71	93	111	137	179	222	311	282	286	290
COGS	—	—	-81	-105	-126	164	190	278	-270	-267	283
Gross profit	—	—	—	—	—	15	32	33	—	—	7
	61	68	168	213	256	6	8	9	549	542	9
	1	3	6	3	7	9	24	24	2	10	-2
OPM %	1.3%	4.4%	6.4%	2.8%	4.8%	4.8%	11%	7.7%	0.9%	3.6%	-0.7%
Depreciation	—	—	0	—	0	0	1	1	1	1	1
Interest	1	1	1	1	1	1	1	1	1	1	1
	0	0	0	0	1	0	1	0	1	1	1
Profit before tax	0	2	5	2	6	7	24	23	3	10	-3
Tax	0	1	2	1	2	2	6	6	0	3	0
Tax %	35.6%	37%	34.8%	29.2%	26.8%	27.4%	27.2%	26.2%	14.3%	28.1%	11.1%
	0	2	3	2	4	5	17	17	2	7	-3
PAT margin %	0.5%	2.2%	3.5%	1.4%	3.1%	3%	7.8%	5.4%	0.8%	2.5%	-1.1%
EPS (₹)	1	5.1	10.4	5	13.7	17.3	55.6	53.8	7	24.3	-10.7
EPS adjusted (₹)	—	—	—	—	—	17.3	55.6	53.8	7	23	-10.7
	0%	0%	0%	0%	0%	0%	1.8%	1.9%	14.3%	4.1%	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3
Reserves	27	44	60	62	69	65
	9	8	19	—	—	11
	19	30	34	57	50	46
Total equity & liabilities	57	85	116	122	121	124
	9	10	11	11	10	12
CWIP	0	0	—	—	—	1
Investments	0	0	2	3	4	4
	48	75	104	108	107	108
Total assets	57	85	116	122	121	124

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	5	18	-9	9	-10	9
	-3	-1	-3	-0	0	-3
	-2	-2	10	-11	0	-0
Net cash flow	0	14	-3	-2	-10	6
Free cash flow	3	17	-11	9	-11	6
CFO / Operating profit %	55.7%	73.1%	-39.5%	382.5%	-98.6%	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	8.3%	14.4%	10.6%	—	—	2.3%
EBITDA margin %	2.8%	4.8%	4.8%	11%	7.7%	0.9%	3.6%	-0.7%
EBIT margin %	2.8%	4.5%	4.6%	10.7%	7.5%	0.6%	3.4%	-1%
PAT margin %	1.4%	3.1%	3%	7.8%	5.4%	0.8%	2.5%	-1.1%
Working capital
Receivable days	—	—	67	72	60	90	72	64
Inventory days	—	—	25	24	43	27	50	56
Payable days	—	—	39	45	0	62	51	55
NWC days	—	—	53	51	103	55	71	66
Leverage
Current ratio	—	—	1.73	1.98	1.87	—	—	1.86
Debt to EBITDA	—	—	1.01	0.31	0.78	—	—	—
Debt to equity	—	—	0.3	0.16	0.3	—	—	0.16
Interest coverage	3.3	6.9	6.8	36.3	19.3	4.6	15.7	-2.1
Asset turnover	—	—	3.12	2.62	2.67	2.31	2.35	2.33
Return ratios
Return on assets %	—	—	9.3%	20.3%	14.3%	1.8%	5.9%	-2.7%
Return on capital employed %	—	—	28.7%	62.8%	43%	—	—	-3%
Return on equity %	—	—	18%	36.7%	26.3%	3.3%	9.9%	-4.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	48.64%	48.64%	48.64%	48.64%	48.95%	49.09%	49.09%	49.09%	49.09%	49.09%	49.09%	49.09%
	3.24%	3.24%	3.24%	3.24%	3.24%	3.24%	3.24%	0%	3.24%	3.24%	3.24%	3.24%
DII	0%	0.42%	0.22%	0.22%	0.22%	0%	0%	3.24%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	48.12%	47.7%	47.9%	47.9%	47.59%	47.67%	47.67%	47.67%	47.67%	47.67%	47.67%	47.67%
No. of shareholders	—	—	—	—	—	—	—	—	6,699	6,488	6,311	6,330

Promoter holding up 0.45 percentage points since Sep 2023.

11 deals · 20 Dec 2021 – 9 Sept 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
9 Sept 2024	GOLECHHA GLOBAL FINANCE LIMITED	Bulk	BSE	Sell	16,000	₹426.16	₹0.68 Cr
7 Aug 2023	ALERT CONSULTANTS & CREDIT PRIVATE LIMITED	Bulk	BSE	Sell	21,769	₹345.74	₹0.75 Cr
7 Aug 2023	SETU SECURITIES PVT. LTD.	Bulk	BSE	Sell	15,602	₹341.65	₹0.53 Cr
7 Aug 2023	SETU SECURITIES PVT. LTD.	Bulk	BSE	Buy	15,602	₹344.43	₹0.54 Cr
27 Jul 2023	GOLECHHA GLOBAL FINANCE LIMITED	Bulk	BSE	Sell	23,630	₹405.82	₹0.96 Cr
18 Aug 2022	HARISHKUMARGUPTA	Bulk	BSE	Buy	22,000	₹629.20	₹1.38 Cr
10 Jan 2022	MALA R BHAVNANI	Bulk	BSE	Sell	28,294	₹454.53	₹1.29 Cr
7 Jan 2022	MALA R BHAVNANI	Bulk	BSE	Sell	78,000	₹404.45	₹3.15 Cr
7 Jan 2022	ADVANI PRIVATE LIMITED	Bulk	BSE	Buy	68,000	₹404.22	₹2.75 Cr
23 Dec 2021	TINA GOYAL	Bulk	BSE	Buy	18,800	₹322.52	₹0.61 Cr

1–10 of 11

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. LALIT DAMODAR MEHTAExecutive Director-Chairperson-MD
Mr. RAJESH LALIT MEHTAExecutive Director
Mr. MEGH RAJESH MEHTAExecutive Director
Mr. MANISHKUMAR INDULAL PIPALIANon-Executive - Independent Director
Mr. SACHIN SAMIR KOTHARYNon-Executive - Independent Director
Mrs. MEGHA SANJAY JAINNon-Executive - Independent Director
Mr. PIYUSH GANGJI DHARODNon-Executive - Independent Director
Rajesh MehtaChief Financial Officer
Mr. Nishant KankariaCompany Secretary cum Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Samrat Pharmachem Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Nov 2026 · in 44 daysresults

4

Final dividend18 Sept 2025 · ex-date₹1
Final dividend19 Sept 2024 · ex-date₹1
Dividend dividend18 Sept 2023 · ex-date₹1
Dividend dividend22 Sept 2022 · ex-date₹1

2

Board meeting to consider results14 Nov 2026
Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

8 announcementsExport CSV

2 Sept 2026, 2:28 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	8.3%	14.4%	10.6%	—	—	2.3%
EBITDA margin %	2.8%	4.8%	4.8%	11%	7.7%	0.9%	3.6%	-0.7%
EBIT margin %	2.8%	4.5%	4.6%	10.7%	7.5%	0.6%	3.4%	-1%
PAT margin %	1.4%	3.1%	3%	7.8%	5.4%	0.8%	2.5%	-1.1%
Working capital
Receivable days	—	—	67	72	60	90	72	64
Inventory days	—	—	25	24	43	27	50	56
Payable days	—	—	39	45	0	62	51	55
NWC days	—	—	53	51	103	55	71	66
Leverage
Current ratio	—	—	1.73	1.98	1.87	—	—	1.86
Debt to EBITDA	—	—	1.01	0.31	0.78	—	—	—
Debt to equity	—	—	0.3	0.16	0.3	—	—	0.16
Interest coverage	3.3	6.9	6.8	36.3	19.3	4.6	15.7	-2.1
Asset turnover	—	—	3.12	2.62	2.67	2.31	2.35	2.33
Return ratios
Return on assets %	—	—	9.3%	20.3%	14.3%	1.8%	5.9%	-2.7%
Return on capital employed %	—	—	28.7%	62.8%	43%	—	—	-3%
Return on equity %	—	—	18%	36.7%	26.3%	3.3%	9.9%	-4.9%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
2 Sept 2026, 2:28 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
27 Aug 2026, 8:42 pm	Corp. Action Book Closure	Book Closure: Sunday, September 20, 2026 To Tuesday, September 22, 2026 (Both Days Inclusive)	PDF
27 Aug 2026, 8:37 pm	AGM/EGM AGM	34Th Annual General Meeting Of Samrat Pharmachem Limited To Be Held On Wednesday, September 23, 2026	PDF
27 Aug 2026, 8:04 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
19 Aug 2026, 2:25 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
14 Aug 2026, 8:14 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today	PDF
17 Jul 2026, 3:44 pm	Company Update Appointment of Statutory Auditor/s	Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s	PDF
17 Jul 2026, 2:58 pm	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF

Samrat Pharmachem Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Credit ratings

Events

Upcoming and recent1

Dividends4

Board meetings2

Announcements

Upcoming and recent1

Dividends4

Board meetings2

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Credit ratings

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

4

2

1

4

2